From the Project CBD Archives:
Excerpted from “CBD: What Does the Science Say?” by By Linda Parker, Erin M. Rock, and Raphael Mechoulam.
Adapted from “Medical Marijuana: Dr. Kogan’s Evidence-Based Guide to the Health Benefits of Cannabis and CBD by Dr. Mikhail Kogan and Joan Liebmann-Smith, PhD.
Medical scientists validate patient accounts of CBD and cannabis for symptom relief.
New studies explore the analgesic effects of cannabis in migraine sufferers and the potential roles of THC, terpenes, and inflammation.
From the Project CBD Patient Survey:
See the full survey here.
2,202 survey respondents reported taking CBD for pain
65% Female | 33% Male | 2% Prefer not to say
The vast majority of participants taking CBD for pain stated that they turned to CBD because they had pain most, if not all, the time (87%). Many had identified multiple sources of pain, the most significant being inflammation. Almost 10% of participants with pain indicated in the comments field that they had arthritis and/or fibromyalgia. Other health issues were common among those with pain, in particular, sleep problems (51%), mood issues (typically anxiety and/or depression) (51%), hormonal conditions (15%), PTSD (14%), and gastrointestinal disease (12%).
Sources of Pain:
Participants were asked to rate their pain with and without CBD on a scale of 1 to 10 where 1 represented “a little pain” and 10 represented “the worst pain imaginable.” They were also asked about changes in the frequency, duration, and intensity of their pain. Participants reported meaningful improvement against all pain measures. Just under 90% of participants reported some improvements in the frequency and duration of their pain, with 60% reporting that CBD made these aspects “much better.”
Most significant though was CBD’s impact on the intensity of pain. Almost 70% of participants reported that their pain intensity was “much better” with CBD; an additional 23% reported it was “a little better.” Without CBD, the average pain score was 6.85. With CBD, the average pain score was 2.76, representing an average decrease in intensity of 60%.
In light of the well-known dangers of opiates, this suggests that CBD has significant potential as a non- toxic, non-addictive, alternative pain remedy.
- Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
- Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain
- Cannabis, pain, and sleep: Sativex Clinical Trials
- Sativex successfully treats neuropathic pain characterised by allodynia: clinical trial
- Cannabinoids for neuropathic pain
- Neuropathic orofacial pain: Cannabinoids as a therapeutic avenue
- Oromucosal delta9-THC/CBD for neuropathic pain associated with multiple sclerosis
- The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain
- Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation
- Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy
- Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain
- Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action
- Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors
- Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes
- Cannabinoids in the management of difficult to treat pain
- Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain
- Marijuana extract helps prevent chemo pain
- Pot users less likely to take painkillers
- CBD & THC interactions on acute pain and locomotor activity
- CBD is a potential therapeutic for the affective-motivational dimension of incision pain in rats